Skip to content

Sublingual Ketamine for Depression and Anxiety: A Retrospective Study of Real-World Clinical Outcomes

Lauren N. Swanson, Lila S. Jones, Jose Muñoz Aycart, Zhipeng Zhu, David M. Rabin, Taylor Kuhn

medRxiv Preprint Server January 30, 2024 preprint DOI: 10.1101/2024.01.30.24301798 (opens in new tab)

Read Full Text
Relevant Not relevant

Study at a glance

AI-extracted from the abstract
Characteristics Observational study
Intervention Ketamine
Topics Anxiety Depression Esketamine Ketamine
Keywords Mental health treatment Ketamine therapy Depression & anxiety Treatment efficacy Safety profile
Key findings Repeated at-home ketamine treatments are effective for depression, generalized anxiety, and social anxiety with a favorable safety profile.

Abstract

Objective To evaluate the effectiveness of repeated at-home ketamine treatments for depression, generalized anxiety, and social anxiety and assess safety in terms of adverse effects and tendency towards long-term use.

Comparable studies

Other observational and cohort studies on ketamine for anxiety, most cited first.

Study Year Design Participants
Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment‐resistant depression Patients with treatment-resistant bipolar depression (B-TRD) and unipolar... 2023 Observational cohort n = 70
The effectiveness of ketamine on anxiety, irritability, and agitation: Implications for treating mixed features in adults with major depressive or bipolar disorder Adults with treatment-resistant major depressive disorder or bipolar disorder 2020 Retrospective analysis n = 201
At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: Findings from a large, prospective, open-label effectiveness trial. Outpatients receiving at-home ketamine-assisted therapy 2022 Prospective study n = 1,247
Predicting outcome with Intranasal Esketamine treatment: A machine-learning, three-month study in Treatment-Resistant Depression (ESK-LEARNING) Treatment-resistant depression patients 2023 Retrospective, multicentric, real-world study n = 149
Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: A viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study Patients with treatment-resistant depression and a substance use disorder 2023 Observational, retrospective, multicentre study n = 26

Citations in the library

Cites 8

and 3 more in the library

Related reading

Explore topics

Anxiety Depression Esketamine Ketamine

By condition and practice

Ketamine for anxiety Ketamine for depression